Ruxolitinib Cream for Pediatric Atopic Dermatitis: What Clinicians Need to KnowÂ
The U.S. Food and Drug Administration (FDA) recently expanded the indication for ruxolitinib cream (Opzelura®) to include children aged 2–11 years with mild-to-moderate atopic dermatitis (AD). This topical, non-steroidal therapy, previously approved for patients 12 years and older, offers a new, targeted approach to managing pediatric AD while reducing concerns associated with chronic corticosteroid use. […]
The Psychosocial Burden of Atopic Eczema: Prevalence of Mental Illness in AE Patients
Atopic dermatitis (AD), or eczema, is a cause of suffering for many U.S. adults, impacting not only their skin health but also productivity levels, mental health, and quality of life. Current data reveals the high prevalence and disease burden of atopic eczema, with an estimate of 16.5 million adult cases and 6.6 million of those […]
